Avalo Therapeutics reported Phase 2 success for abdakibart in hidradenitis suppurativa, meeting the trial’s primary endpoint on the HiSCR75 response rate at week 16 in the Lotus study. Shares jumped on the topline outcome, and Avalo said the response supported moving toward registrational Phase 3 work. The randomized Phase 2 design enrolled 253 adults with moderate-to-severe HS and tested two abdakibart dosing regimens against placebo. Avalo framed the dataset as a basis to advance the humanized anti–IL-1β antibody program despite cross-trial comparisons that can be confounded by differing placebo rates.